Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ChAd155-hIi-HBV + MVA-HBV + GSK3528869A
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Intramuscular
01
Overview
This combination therapeutic vaccine regimen for chronic hepatitis B consists of two viral vector-based vaccines—**ChAd155-hIi-HBV** (a chimpanzee adenovirus vector encoding hepatitis B virus antigens), **MVA-HBV** (a Modified Vaccinia Ankara virus vector encoding HBV antigens)—administered with GSK3528869A, which is an adjuvanted recombinant protein formulation. The approach is designed to restore or boost immune responses against hepatitis B virus, aiming for the immunological control of chronic infection and potentially allowing discontinuation of conventional nucleos(t)ide analogue therapy without viral rebound. It is being developed and trialed primarily for adult patients with chronic hepatitis B who are currently under suppressive antiviral therapy. The regimen uses a **prime-boost** strategy (using viral vectors first, then protein boost) aimed at eliciting robust and sustained anti-HBV immune responses, particularly targeting hepatitis B surface antigen (HBsAg) reduction[1][4][5][7][8][9].
- Other names
- ChAd-hli-HBV + MVA-HBV + GSK3528869AHBV viral vector and adjuvanted proteins vaccine
02
Targets
HBc (Hepatitis B virus core protein)HBsAg (Hepatitis B surface antigen)CD74 (Major histocompatibility complex class II invariant chain)
Beyond the preview
Go deeper on ChAd155-hIi-HBV + MVA-HBV + GSK3528869A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ChAd155-hIi-HBV + MVA-HBV + GSK3528869A.